Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proinsulin-peptide C19-A3-pulsed tolerogenic dendritic cells
- Development stage
- Unknown
- Lead developer
- Leiden University Medical Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
proinsulin-peptide C19-A3-pulsed tolerogenic dendritic cells (PIpepTolDC) is an autologous cell-based immunotherapy developed by Leids Universitair Medisch Centrum (LUMC) and City of Hope National Medical Center for the treatment of type 1 diabetes mellitus (T1D). The therapy consists of a patient's own (autologous) tolerogenic dendritic cells (tolDCs), derived from CD14+ monocytes collected via leukapheresis, which are matured ex vivo (typically using vitamin D3 and dexamethasone) and loaded ('pulsed') with the naturally derived proinsulin peptide C19-A3. PIpepTolDC acts as an 'inverse vaccine' designed to restore immune tolerance by presenting the C19-A3 peptide to suppress proinflammatory, autoreactive T-cell responses and induce antigen-specific regulatory T cells (Tregs), thereby halting the autoimmune destruction of insulin-producing pancreatic beta cells. It has been evaluated in Phase 1 clinical trials (such as the D-Sense trial) demonstrating safety, feasibility, and a durable reduction in autoimmune responses.
- Other names
- autologous tolerogenic proinsulin peptide-loaded dendritic cells PIpepTolDCproinsulin peptide-loaded tolerogenic dendritic cellsPIpepTolDC vaccine
02
Targets
Proinsulin-specific T-cell receptors recognizing the C19-A3 peptide-HLA-DR4 complexHLA-DR4
Beyond the preview
Go deeper on proinsulin-peptide C19-A3-pulsed tolerogenic dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proinsulin-peptide C19-A3-pulsed tolerogenic dendritic cells.